• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Lifecore Biomedical Appoints Brikkelle Thompson as Senior Vice President of Human Resources

    9/10/24 7:00:23 AM ET
    $LFCR
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $LFCR alert in real time by email

    CHASKA, Minn., Sept. 10, 2024 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ:LFCR) ("Lifecore" or the "Company"), a fully integrated contract development and manufacturing organization ("CDMO"), today announced the appointment of Brikkelle Thompson as senior vice president of human resources. Ms. Thompson brings nearly 25 years of visionary human resources leadership, global experience, and deep talent management to Lifecore, including 14 years in the medical technology, medical device, and healthcare industries. She will be charged with enhancing the company's performance-driven culture, while further strengthening the Lifecore team by maintaining and securing exceptional talent.

    "As we continue to sharpen and execute our growth strategy to maximize value for our stakeholders, we are keenly aware that our corporate culture and team will be essential to successfully achieving our vision for the business. In Brikkelle, we have added an exceptional HR executive who has a well-earned reputation for elevating companies by building teams with top-level talent from across the country while fostering performance-driven cultures," said Paul Josephs, president and chief executive officer. "We feel fortunate to add Brikkelle as a strategic partner to our operations team and are eager to see the important contributions she makes in aligning our mission, values, culture, and team toward our ultimate goal of consistent and meaningful growth."

    Ms. Thompson has a successful track record of partnering with organizational leaders to architect and deliver HR strategies to optimize the employee experience and enhance organizational performance. Her leadership spans from small organizations to Fortune 100 companies in public and private sectors. Prior to joining Lifecore, she held the position of head of human resources – the Americas at Teleflex. Ms. Thompson has also served as vice president of human resources for Nonin Medical, where she reported directly into the CEO and instituted an HR Business Partner model that positioned HR as the strategic, proactive and collaborative partner to company-wide leadership. Her career also includes nearly a decade tenure with Medtronic, where she held the position of global executive development program manager, as well as serving as talent development consultant.

    About Lifecore Biomedical

    Lifecore Biomedical, Inc. (NASDAQ:LFCR) is a fully integrated contract development and manufacturing organization (CDMO) that offers highly differentiated capabilities in the development, fill and finish of sterile injectable pharmaceutical products in syringes, vials, and cartridges, including complex formulations. As a leading manufacturer of premium, injectable-grade hyaluronic acid, Lifecore brings more than 40 years of expertise as a partner for global and emerging biopharmaceutical and biotechnology companies across multiple therapeutic categories to bring their innovations to market. For more information about the Company, visit Lifecore's website at www.lifecore.com.



    Lifecore Biomedical, Inc. Contact Information:
    
    Vida Strategic Partners
    Stephanie Diaz (Investors)
    415-675-7401
    [email protected]
    
    Tim Brons (Media)
    415-675-7402
    [email protected]

    Primary Logo

    Get the next $LFCR alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $LFCR

    DatePrice TargetRatingAnalyst
    3/17/2026$5.50Mkt Perform → Outperform
    Barrington Research
    9/4/2025Sector Weight
    KeyBanc Capital Markets
    5/21/2025Outperform
    William Blair
    9/5/2024$8.00Buy
    Craig Hallum
    8/28/2024Outperform → Mkt Perform
    Barrington Research
    3/20/2023$11.00 → $2.00Overweight → Equal-Weight
    Stephens
    More analyst ratings

    $LFCR
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Josephs Paul bought $97,580 worth of shares (17,000 units at $5.74), increasing direct ownership by 3% to 559,717 units (SEC Form 4)

    4 - LIFECORE BIOMEDICAL, INC. \DE\ (0001005286) (Issuer)

    1/8/25 4:10:19 PM ET
    $LFCR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Large owner Wynnefield Partners Small Cap Value Lp I bought $1,200,000 worth of shares (292,683 units at $4.10) (SEC Form 4)

    4 - LIFECORE BIOMEDICAL, INC. \DE\ (0001005286) (Issuer)

    10/7/24 8:45:10 PM ET
    $LFCR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LFCR
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Lifecore Biomedical Signs Commercial Site Transfer Agreement with Leading Medical Aesthetics Company

    -- Agreement for the Commercial Manufacture of Established, Approved Aesthetic Product -- -- Third Commercial Site Transfer Agreement Win in Five Months -- -- Program Expected to Generate Commercial Revenue in 24 Months, Contributing to 2029 Revenue CAGR -- CHASKA, Minn., March 23, 2026 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ:LFCR) ("Lifecore"), a fully integrated injectables contract development and manufacturing organization ("CDMO"), today announced that it has signed a CDMO manufacturing services agreement with a new aesthetics customer for an established, market-approved product. Under the terms of the agreement, Lifecore will perform technical transfer services inclu

    3/23/26 7:00:00 AM ET
    $LFCR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Lifecore Biomedical Reports Financial Results for the Fourth Quarter and Transition Period Ended December 31, 2025, and Provides Corporate Update

    -- Recorded Fourth Quarter Revenues of $35.7 Million and Transition Period Revenues of $75.5 Million -- -- Multiple New Programs Signed in Fourth Quarter 2025 Including Two Commercial Site Transfer Programs, for Total of Five New Programs in 2025 Transition Period -- -- Organizational Initiatives Drive Further Improvement in Margins -- Conference Call Today at 8:30am ET CHASKA, Minn., March 16, 2026 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ:LFCR) ("Lifecore" or the "Company"), a fully integrated injectables contract development and manufacturing organization ("CDMO"), today announced strong results for the fourth quarter and transition period ended December 31, 2025

    3/16/26 8:00:00 AM ET
    $LFCR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Lifecore Biomedical to Participate in 6th Annual KeyBanc Capital Markets Healthcare Virtual Forum

    CHASKA, Minn., March 10, 2026 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) ("Lifecore"), a fully integrated injectables contract development and manufacturing organization ("CDMO"), today announced that the company will participate in the upcoming KeyBanc Capital Markets Healthcare Virtual Forum. Details regarding Lifecore's participation are as follows: 6th Annual KeyBanc Capital Markets Healthcare Virtual Forum Details: Mr. Josephs will be a featured speaker in a fireside chat and Lifecore management will participate in investor meetingsConference Dates: March 17 – 18, 2026Fireside Chat Time/Date: 9:00am – 9:35am Eastern Time on Tuesday, March 17, 2026, webcast availabl

    3/10/26 4:05:00 PM ET
    $LFCR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LFCR
    SEC Filings

    View All

    SEC Form 10-KT filed by Lifecore Biomedical Inc.

    10-KT - LIFECORE BIOMEDICAL, INC. \DE\ (0001005286) (Filer)

    3/16/26 8:15:18 AM ET
    $LFCR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Lifecore Biomedical Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - LIFECORE BIOMEDICAL, INC. \DE\ (0001005286) (Filer)

    3/16/26 8:08:06 AM ET
    $LFCR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Lifecore Biomedical Inc. filed SEC Form 8-K: Shareholder Director Nominations

    8-K - LIFECORE BIOMEDICAL, INC. \DE\ (0001005286) (Filer)

    3/5/26 4:33:56 PM ET
    $LFCR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LFCR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Lifecore Biomedical upgraded by Barrington Research with a new price target

    Barrington Research upgraded Lifecore Biomedical from Mkt Perform to Outperform and set a new price target of $5.50

    3/17/26 7:45:07 AM ET
    $LFCR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    KeyBanc Capital Markets initiated coverage on Lifecore Biomedical

    KeyBanc Capital Markets initiated coverage of Lifecore Biomedical with a rating of Sector Weight

    9/4/25 9:01:33 AM ET
    $LFCR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    William Blair initiated coverage on Lifecore Biomedical

    William Blair initiated coverage of Lifecore Biomedical with a rating of Outperform

    5/21/25 8:58:30 AM ET
    $LFCR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LFCR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Legal & Administration Salus Thomas D. was granted 30,000 shares, increasing direct ownership by 12% to 270,978 units (SEC Form 4)

    4 - LIFECORE BIOMEDICAL, INC. \DE\ (0001005286) (Issuer)

    3/2/26 6:52:42 PM ET
    $LFCR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Financial Officer Lake Ryan David covered exercise/tax liability with 22,932 shares, decreasing direct ownership by 6% to 336,691 units (SEC Form 4)

    4 - LIFECORE BIOMEDICAL, INC. \DE\ (0001005286) (Issuer)

    9/4/25 4:42:03 PM ET
    $LFCR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Obus Nelson was granted 19,506 shares, increasing direct ownership by 16% to 138,193 units (SEC Form 4)

    4 - LIFECORE BIOMEDICAL, INC. \DE\ (0001005286) (Issuer)

    7/17/25 6:48:53 PM ET
    $LFCR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LFCR
    Leadership Updates

    Live Leadership Updates

    View All

    Lifecore Biomedical Names Mark DaFonseca Chief Commercial Officer

    Mr. DaFonseca Possesses Nearly 30 Years of Broad Drug Development Experience, including More than 15 Years Leading High Performing CDMO Sales Organizations Will Leverage Deep Pharma Services Expertise as Leader of Lifecore's Sales Organization Focused on Executing Three-Pronged Growth Strategy CHASKA, Minn., May 27, 2025 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ:LFCR) ("Lifecore"), a fully integrated contract development and manufacturing organization ("CDMO"), today announced that it has appointed Mark DaFonseca as chief commercial officer.   A seasoned CDMO and pharmaceutical services executive, Mr. DaFonseca has nearly 30 years of pharmaceutical industry experience spannin

    5/27/25 7:00:00 AM ET
    $LFCR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Lifecore Biomedical Appoints Thomas D. Salus as Chief Legal and Administration Officer

    Mr. Salus Brings More than 30 Years of Broad-Based Legal and Management Expertise Highlighted by Extensive Experience within Life Sciences Industry Significantly Elevates Lifecore's Capabilities Across Corporate Governance, Transactional Activities, and SEC Reporting and Compliance CHASKA, Minn., April 14, 2025 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ:LFCR) ("Lifecore"), a fully integrated contract development and manufacturing organization ("CDMO"), today announced that it has appointed Thomas (Tom) Salus as chief legal and administration officer and corporate secretary. A business-focused, hands-on executive, Mr. Salus has more than 30 years of broad-based legal and manage

    4/14/25 7:00:02 AM ET
    $LFCR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Lifecore Biomedical Appoints Thomas Guldager as Vice President, Operations

    Brings Strong Background in Pharmaceutical Manufacturing Operations and Finance to Help Drive Performance and Productivity Jackie Klecker Named Executive Vice President, Quality and Development Services to Focus on Sustaining Company's Strong Regulatory and Compliance Track Record Personnel Moves Bifurcate Operations and Quality Functions to Align with Company's Growth Strategy and Reflect Natural Evolution of Business CHASKA, Minn., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ:LFCR) ("Lifecore"), a fully integrated contract development and manufacturing organization ("CDMO"), today announced that it has appointed Thomas Guldager as vice president, operations. An

    11/4/24 7:00:04 AM ET
    $LFCR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LFCR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Lifecore Biomedical Inc.

    SC 13D/A - LIFECORE BIOMEDICAL, INC. \DE\ (0001005286) (Subject)

    7/5/24 2:17:24 PM ET
    $LFCR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13D/A filed by Lifecore Biomedical Inc.

    SC 13D/A - LIFECORE BIOMEDICAL, INC. \DE\ (0001005286) (Subject)

    7/1/24 4:43:55 PM ET
    $LFCR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13D/A filed by Lifecore Biomedical Inc.

    SC 13D/A - LIFECORE BIOMEDICAL, INC. \DE\ (0001005286) (Subject)

    7/1/24 4:05:39 PM ET
    $LFCR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LFCR
    Financials

    Live finance-specific insights

    View All

    Lifecore Biomedical Reports Financial Results for the Fourth Quarter and Transition Period Ended December 31, 2025, and Provides Corporate Update

    -- Recorded Fourth Quarter Revenues of $35.7 Million and Transition Period Revenues of $75.5 Million -- -- Multiple New Programs Signed in Fourth Quarter 2025 Including Two Commercial Site Transfer Programs, for Total of Five New Programs in 2025 Transition Period -- -- Organizational Initiatives Drive Further Improvement in Margins -- Conference Call Today at 8:30am ET CHASKA, Minn., March 16, 2026 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ:LFCR) ("Lifecore" or the "Company"), a fully integrated injectables contract development and manufacturing organization ("CDMO"), today announced strong results for the fourth quarter and transition period ended December 31, 2025

    3/16/26 8:00:00 AM ET
    $LFCR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Lifecore Biomedical Reports Financial Results for the Three Months Ended September 30, 2025, and Provides Corporate Update

    -- Recorded $31.1 Million in Revenue During the Three Months Ended September 30, 2025, Representing a 26% Increase From Comparable Period of 2024 -- -- Multiple New Programs Signed with New Customers -- -- Continued Improvements in Efficiency and Productivity Across the Organization -- Conference Call Today at 4:30pm ET CHASKA, Minn., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ:LFCR) ("Lifecore"), a fully integrated contract development and manufacturing organization ("CDMO"), today announced its financial results for the three months ended September 30, 2025. Highlights for Three Months Ended September 30, 2025 "We are thrilled with the progress made during t

    11/6/25 4:05:00 PM ET
    $LFCR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Lifecore Biomedical to Report Financial Results for the Three Months Ended September 30, 2025, on November 6, 2025

    CHASKA, Minn., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ:LFCR) ("Lifecore"), a fully integrated contract development and manufacturing organization ("CDMO"), today announced that it will report financial results for the three months ended September 30, 2025, on Thursday, November 6, 2025, after market close. At 4:30 p.m. Eastern Time that day, members of Lifecore's senior management team will host a webcast to discuss the results. To listen to the live webcast, or access the archived webcast, please visit the Investor Events & Presentations page of Lifecore's website at: https://ir.lifecore.com/events-presentations. Following the live webcast, an archived version

    10/30/25 4:05:00 PM ET
    $LFCR
    Biotechnology: Pharmaceutical Preparations
    Health Care